BiotechTube

LY3848575 + Placebo

Phase 2Active
0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Neuropathic Pain

Conditions

Neuropathic Pain, Distal Sensory Polyneuropathy

Trial Timeline

Aug 22, 2024 → Sep 1, 2026

NCT ID
NCT06568042

About LY3848575 + Placebo

LY3848575 + Placebo is a phase 2 stage product being developed by Eli Lilly for Neuropathic Pain. The current trial status is active. This product is registered under clinical trial identifier NCT06568042. Target conditions include Neuropathic Pain, Distal Sensory Polyneuropathy.

What happened to similar drugs?

8 of 20 similar drugs in Neuropathic Pain were approved

Approved (8) Terminated (2) Active (12)
🔄YHD1119 + LyricaYuhanPhase 3
✅pregabalin sustained release tablet + pregabalin immediate release capsuleYuhanApproved
🔄DS-5565 + placeboDaiichi SankyoPhase 3
🔄Mirogabalin + PlaceboDaiichi SankyoPhase 3
🔄DS-5565Daiichi SankyoPhase 3
🔄Placebo + MirogabalinDaiichi SankyoPhase 3
✅Duloxetine + Pregabalin + PlaceboShionogiApproved

Hype Score Breakdown

Clinical
12
Activity
12
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06568042Phase 2Active

Competing Products

20 competing products in Neuropathic Pain

See all competitors
ProductCompanyStageHype Score
CHF6467 activeComac MedicalPhase 1/2
22
LY3857210 + PlaceboEli LillyPhase 2
35
OK-101 0.05% + OK-101 0.1% + PlaceboOKYO PharmaPhase 2
17
YHD1119 + LyricaYuhanPhase 3
40
YHD1119 300mg + YHD1119 300mgYuhanPhase 1
29
pregabalin sustained release tablet + pregabalin immediate release capsuleYuhanApproved
43
DS-5565 + placeboDaiichi SankyoPhase 3
40
Mirogabalin + PlaceboDaiichi SankyoPhase 3
40
DS-1971a + placebo + pregabalinDaiichi SankyoPhase 2
27
DS-5565Daiichi SankyoPhase 3
40
Placebo + MirogabalinDaiichi SankyoPhase 3
40
QutenzaAstellas PharmaPre-clinical
26
Qutenza exposureAstellas PharmaPre-clinical
26
Duloxetine + Pregabalin + PlaceboShionogiApproved
43
LY3016859 + PlaceboEli LillyPhase 2
35
LY3556050 + PlaceboEli LillyPhase 2
27
LY3526318 + PlaceboEli LillyPhase 2
35
LY4065967 + PlaceboEli LillyPhase 2
42
ABT-639 + pregabalin + PlaceboAbbViePhase 2
35
onabotulinum toxin AAbbViePhase 2
35